ACLX Stock Forecast 2025-2026
Distance to ACLX Price Targets
ACLX Price Momentum
10 Quality Stocks Worth Considering Now
Researching Arcellx (ACLX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ACLX and similar high-potential opportunities.
Latest ACLX Stock Price Targets & Analyst Predictions
Based on our analysis of 19 Wall Street analysts, ACLX has a bullish consensus with a median price target of $115.00 (ranging from $104.00 to $134.00). Currently trading at $63.97, the median forecast implies a 79.8% upside. This outlook is supported by 18 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ACLX Analyst Ratings
ACLX Price Target Range
Latest ACLX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ACLX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 10, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $115.00 |
| Dec 10, 2024 | UBS | Ashwani Verma | Buy | Maintains | $114.00 |
| Dec 10, 2024 | Needham | Gil Blum | Buy | Reiterates | $105.00 |
| Dec 9, 2024 | Needham | Gil Blum | Buy | Reiterates | $105.00 |
| Nov 12, 2024 | Truist Securities | Asthika Goonewardene | Buy | Maintains | $136.00 |
| Nov 8, 2024 | Needham | Gil Blum | Buy | Maintains | $105.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $115.00 |
| Nov 8, 2024 | Piper Sandler | Biren Amin | Overweight | Maintains | $115.00 |
| Nov 6, 2024 | Baird | Jack Allen | Outperform | Maintains | $106.00 |
| Nov 6, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $95.00 |
| Nov 6, 2024 | B of A Securities | Jason Gerberry | Buy | Maintains | $100.00 |
| Nov 6, 2024 | Morgan Stanley | Judah Frommer | Overweight | Maintains | $106.00 |
| Nov 6, 2024 | Needham | Gil Blum | Buy | Reiterates | $96.00 |
| Oct 31, 2024 | Needham | Gil Blum | Buy | Reiterates | $96.00 |
| Oct 22, 2024 | Needham | Gil Blum | Buy | Maintains | $96.00 |
| Oct 18, 2024 | Stifel | Benjamin Burnett | Buy | Maintains | $122.00 |
| Oct 17, 2024 | Canaccord Genuity | John Newman | Buy | Maintains | $115.00 |
| Sep 9, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $0.00 |
| Sep 3, 2024 | Cantor Fitzgerald | Rick Bienkowski | Overweight | Initiates | $0.00 |
| Aug 9, 2024 | Needham | Gil Blum | Buy | Reiterates | $81.00 |
Arcellx Inc. (ACLX) Competitors
The following stocks are similar to Arcellx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Arcellx Inc. (ACLX) Financial Data
Arcellx Inc. has a market capitalization of $3.49B with a P/E ratio of 0.0x. The company generates $107.94M in trailing twelve-month revenue with a -99.5% profit margin.
Revenue growth is -75.8% quarter-over-quarter, while maintaining an operating margin of -348.2% and return on equity of -22.8%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Arcellx Inc. (ACLX) Business Model
About Arcellx Inc.
Develops innovative cell therapies for cancer.
Arcellx Inc. generates revenue through the development and commercialization of proprietary cell therapies aimed at treating cancer and other diseases. The company utilizes its D-Domain technology platform to enhance the safety and efficacy of these treatments, targeting malignant cells with precision. Revenue streams may include partnerships, grants, and potential product sales once therapies reach the market.
Arcellx operates within the dynamic biotechnology sector, focusing on personalized medicine and novel cancer therapies. The company's collaborative efforts with academic institutions and strategic partners aim to expedite its research and product development processes. Its commitment to scientific innovation addresses significant unmet medical needs, positioning it as a key player in the biopharmaceutical industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
163
CEO
Mr. Rami Elghandour
Country
United States
IPO Year
N/A
Website
www.arcellx.comArcellx Inc. (ACLX) Latest News & Analysis
Latest News
Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month
1 month agoToday's Marketplace features an interview with Arcellx, Inc. CMO Christopher Heery and Creighton University Nursing Dean Jessica Clark, highlighting insights from both leaders.
The interview highlights Arcellx's leadership and potential developments, which could signal growth opportunities or strategic insights relevant to investors.
Arcellx, Inc. has appointed Andrew Galligan and Kristin Myers to its Board of Directors, enhancing its leadership with expertise in finance and healthcare.
Leadership changes can signal strategic shifts and impact company direction, potentially affecting stock performance and investor confidence in Arcellx's growth prospects.
Arcellx Impressive Safety Data Leaves Doubts
1 month agoArcellx's cell therapy shows potential for multiple myeloma treatment, backed by strong trial results and partnerships, though clarity on safety results is needed for investor confidence.
Arcellx's cell therapy for multiple myeloma presents growth potential, backed by positive trial results and partnerships. However, clarity on safety results is crucial for assessing investment risks.
Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights
1 month agoArcellx, Inc. (NASDAQ: ACLX) reported Q4 and full-year 2024 results, highlighting progress in its cell therapy, anito-cel, in collaboration with Kite, showcasing promising ASH data.
Arcellx's promising ASH data on anito-cel may enhance investor confidence, potentially impacting stock performance and future funding opportunities in the biotech sector.
Arcellx, Inc. (ACLX) reported a quarterly loss of $0.87 per share, exceeding the Zacks Consensus Estimate of a $0.63 loss, compared to earnings of $0.42 per share last year.
Arcellx's larger-than-expected quarterly loss may signal worsening financial health, impacting investor confidence and stock performance. Comparisons to prior earnings highlight a significant downturn.
Arcellx, Inc. (NASDAQ: ACLX) will participate in a fireside chat at the TD Cowen Health Care Conference on March 5 at 1:10 p.m. ET, with a live webcast available on their website.
Arcellx's participation in a major healthcare conference may boost visibility and investor interest, potentially impacting stock performance and investor sentiment.
Frequently Asked Questions About ACLX Stock
What is Arcellx Inc.'s (ACLX) stock forecast for 2025?
Based on our analysis of 19 Wall Street analysts, Arcellx Inc. (ACLX) has a median price target of $115.00. The highest price target is $134.00 and the lowest is $104.00.
Is ACLX stock a good investment in 2025?
According to current analyst ratings, ACLX has 18 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $63.97. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ACLX stock?
Wall Street analysts predict ACLX stock could reach $115.00 in the next 12 months. This represents a 79.8% increase from the current price of $63.97. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Arcellx Inc.'s business model?
Arcellx Inc. generates revenue through the development and commercialization of proprietary cell therapies aimed at treating cancer and other diseases. The company utilizes its D-Domain technology platform to enhance the safety and efficacy of these treatments, targeting malignant cells with precision. Revenue streams may include partnerships, grants, and potential product sales once therapies reach the market.
What is the highest forecasted price for ACLX Arcellx Inc.?
The highest price target for ACLX is $134.00 from at , which represents a 109.5% increase from the current price of $63.97.
What is the lowest forecasted price for ACLX Arcellx Inc.?
The lowest price target for ACLX is $104.00 from at , which represents a 62.6% increase from the current price of $63.97.
What is the overall ACLX consensus from analysts for Arcellx Inc.?
The overall analyst consensus for ACLX is bullish. Out of 19 Wall Street analysts, 18 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $115.00.
How accurate are ACLX stock price projections?
Stock price projections, including those for Arcellx Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.